Original Research Article

- 2 Title Page
- 3 **Title**

1

5

- 4 Tocilizumab and steroid treatment in patients with COVID-19 pneumonia.
- 6 Authors
- 7 Malgorzata Mikulska ^{1,2*}, Laura Ambra Nicolini ², Alessio Signori ³, Antonio Di Biagio ^{1,2},
- 8 Chiara Sepulcri ¹, Chiara Russo ¹, Silvia Dettori ¹, arco Berruti ¹, Maria Pia Sormani ³, Daniele
- 9 Roberto Giacobbe ^{1,2}, Antonio Vena ², Andrea De Maria ^{1,2}, Chiara Dentone ², Lucia
- Taramasso ², Michele Mirabella ^{1,2}, Laura Magnasco ^{1,2}, Sara Mora ⁴, Emanuele Delfino ²,
- 11 Federica Toscanini ², Elisa Balletto ^{1,2}, Anna Ida Alessandrini ², Federico Baldi ¹, Federica
- 12 Briano ¹, Marco Camera ², Ferdinando Dodi ², Antonio Ferrazin ², Laura Labate ¹, Giovanni
- 13 Mazzarello ², Rachele Pincino ¹, Federica Portunato ^{2,5}, Stefania Tutino ¹, Emanuela Barisione
- 6, Bianca Bruzzone 7, Andrea Orsi 7,8, Eva Schenone 2, Nirmala Rosseti 2, Elisabetta Sasso 9,
- 15 Giorgio Da Rin 10, Paolo Pelosi 11,12, Sabrina Beltramini 9, Mauro Giacomini 4, Giancarlo
- 16 Icardi ^{7,8}, Angelo Gratarola ¹³, Matteo Bassetti ^{1,2}

18 Affiliations

- 19 1. Division of Infectious Diseases, Department of Health Sciences (DISSAL), University of
- 20 Genoa, Genoa, Italy
- 2. Division of Infectious Diseases, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
- 22 3. Section of Biostatistics, Department of Health Sciences, University of Genova, Genova,
- 23 Italy
- 4. Department of Informatics, Bioengineering, Robotics and System Engineering, University
- of Genoa, Genoa, Italy
- 5 Infectious Diseases Unit, University of Campania Luigi Vanvitelli, Napoli

- 27 6. Interventional Pulmonology Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
- 7. Hygiene Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
- 8. Department of Health Sciences, University of Genoa
- 30 9. Pharmacy Complex Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy
- 31 10. Medicine Laboratory, IRCCS Ospedale Policlinico San Martino, Genova, Italy
- 32 11. Department of Surgical Sciences and Integrated Diagnostics, University of Genova,
- 33 Genova, Italy

- 34 12. Anesthesia and Intensive Care, San Martino Policlinico Hospital, IRCCS for Oncology
- 35 and Neurosciences, Genoa, Italy
- 36 13. Department of Emergency and Urgency, San Martino Policlinico Hospital, IRCCS for
- 37 Oncology and Neurosciences, Genoa, Italy
- 39 *Corresponding author
- 40 m.mikulska@unige.it (MM)

42 Abstract 43 Introduction 44 Coronavirus disease 2019 (COVID-19) can lead to respiratory failure due to severe immune 45 response. Treatment targeting this immune response might be beneficial but there is limited 46 evidence on its efficacy. 47 The aim of this study was to determine if early treatment of patients with COVID-19 48 pneumonia with tocilizumab and/or steroids was associated with better outcome. 49 Methods 50 This observational single-center study included patients with COVID-19 pneumonia who 51 were not intubated and received either standard of care (SOC, controls) or SOC plus early 52 (within 3 days from hospital admission) anti-inflammatory treatment. SOC consisted of 53 hydroxychloroquine 400mg bid plus, in those admitted before March 24th, also 54 darunavir/ritonavir. Anti-inflammatory treatment consisted of either tocilizumab (8mg/kg 55 intravenously or 162mg subcutaneously) or methylprednisolone 1 mg/kg for 5 days or both. 56 Failure was defined as intubation or death, and the endpoints were failure-free survival 57 (primary endpoint) and overall survival (secondary) at day 30. Difference between the groups 58 was estimated as Hazard Ratio by a propensity score weighted Cox regression analysis 59 $(HR_{OW}).$ 60 Results 61 Overall, 196 adults were included in the analyses. They were mainly male (67.4%), with 62 comorbidities (78.1%) and severe COVID-19 pneumonia (83.7%). Median age was 67.9 63 years (range, 30-100) and median PaO₂/FiO₂ 200 mmHg (IQR 133-289). Among them, 64 130 received early anti-inflammatory treatment with: tocilizumab (n=29, 22.3%), 65 methylprednisolone (n=45, 34.6%), or both (n=56, 43.1%). The adjusted failure-free survival 66 among tocilizumab/methylprednisolone/SOC treated patients vs. SOC was 80.8% (95%CI, 67 72.8-86.7) vs. 64.1% (95%CI, 51.3-74.0), HR_{OW} 0.48, 95%CI, 0.23-0.99; p=0.049. The

- 68 overall survival among tocilizumab/methylprednisolone/SOC patients vs. SOC was 85.9%
- 69 (95%CI, 80.7-92.6) vs. 71.9% (95%CI, 46-73), HR_{OW} 0.41, 95%CI: 0.19-0.89, p=0.025.
- 70 Conclusion

74

- 71 Early adjunctive treatment with tocilizumab, methylprednisolone or both may improve
- outcomes in non-intubated patients with COVID-19 pneumonia.
- 75 Keywords: Tocilizumab, interleukin-6, SARS-CoV-2, steroids, pneumonia, ARDS, COVID-
- 76 19, treatment.

Introduction

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

Pandemic coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 coronavirus has recently emerged [1]. Although most of the infected patients will remain asymptomatic or develop mild symptoms, up to 20% may develop severe disease with pneumonia and respiratory failure [2]. Oxygen administration is the cornerstone of supportive treatment and is required in approximately 15% of cases, while invasive mechanical ventilation is necessary in up to 5-7% of severe cases [3-5]. Since mortality in patients with invasive ventilation can be very high, halting the progression from moderate to severe respiratory failure should reduce the mortality in COVID-19 [6]. At the beginning of COVID-19 pandemics, based on the experience with previous studies in viral pneumonia, including SARS-CoV and MERS, the use of steroids was discouraged, mainly due to undocumented benefit and fearing potential increase in viral proliferation and side effects [7, 8]. However, with the increasing knowledge about COVID-19, a biphasic model of the disease has been proposed [9, 10]. According to this model, the first phase is caused directly by viral replication, while in the second phase, the symptoms and respiratory failure are due to inflammatory response, and could be treated with agents which reduce inflammation, such as corticosteroids, or inhibitors of pro-inflammatory interleukins and Janus kinase (JAK) [9-11]. Indeed, some real life experiences in COVID-19 patients showed that the use of antiinflammatory treatments might be beneficial [12]. In fact, short-term steroid therapy was associated with lower mortality in 201 patients with acute respiratory distress syndrome (ARDS) [13]. Additionally, following the data on presence of inflammatory cytokine storm in severe COVID-19, tocilizumab use has been advocated. This monoclonal antibody, which binds to interleukin 6 (IL-6) receptor and blocks the IL-6 mediated inflammatory response, is approved for treatment of rheumatologic disorders and cytokine-release syndrome associated

with Chimeric Antigen Receptor T-cell (CAR-T) administration. It was reported to reduce COVID-19-associated inflammation, and was approved in China for this indication [12, 14]. Based on the first evidences, we formulated the hypothesis of potential benefit of anti-inflammatory treatment, and progressively modified our therapeutic approach to COVID-19. We started using tocilizumab in patients with respiratory failure, and subsequently, we introduced into our protocol early administration of methylprednisolone treatment, followed in more severe cases by the administration of tocilizumab.

We hypothesized that outcomes such as no need for intubation and survival of patients with severe COVID-19 pneumonia in whom tocilizumab and/or methylprednisolone were administered in addition to standard of care (SOC) could be better than in those who received only SOC.

Patients and methods

Setting and patients

In this observational single-center study, adult patients admitted to the San Martino University Hospital, Genova, Italy, for COVID-19 pneumonia were included as cases if treated with tocilizumab and/or methylprednisolone, not intubated, not treated with remdesivir and not pregnant. The outcomes of patients treated with tocilizumab/methylprednisolone were compared to data from consecutive patients admitted to our hospital for COVID-19 pneumonia who received only SOC, mainly because they were admitted before the routine use of tocilizumab/methylprednisolone (control group).

All patients provided an informed consent for treatment with off label agents according to the local protocol approved by Hospital Authorities, for data collection and for participation in the study. The study was carried out in accordance with the principles of the Declaration of Helsinki and approved by the Regional Ethic Committee (N. CER Liguria 114/2020-ID 10420).

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

Data collection and definitions Data were collected from hospital information system by a standard based automatic procedure and stored in an online database with pseudo-anonymization features suitable for secondary use of clinical data [15]. Controls were identified through this prospectively collected database of hospital-admitted COVID-19 patients. Patients who had any of the following features at the time of, or after, admission were classified as having severe pneumonia: (1) respiratory distress (≥30 breaths per min); or (2) oxygen saturation at rest ≤93%; or (3) ratio of partial pressure of arterial oxygen to fractional concentration of oxygen inspired air (PaO₂/FiO₂) ≤300 mm Hg; or (4) severe disease complications (e.g., respiratory failure, requirement of mechanical ventilation, septic shock, or non-respiratory organ failure) [7, 14, 15]. Systemic inflammation was defined as presence at baseline of one of the following: fever > 38°C, C-reactive protein (CRP) 10 times above the upper limit of normal (ULN) of 5 mg/dl, ferritin 2 times above the ULN (400 µg/L), or IL-6 10 times above the ULN of 3.4 ng/L. The first results obtained at hospital admission, and in any case not later than within day 3 of admission were considered. Adverse events possibly or probably related to steroid and tocilizumab treatment, such as neutropenia, anemia, thrombocytopenia, increase in alanine aminotransferase (ALT) levels, (UNL < 40 U/L), microbiologically documented infections and allergic reactions were evaluated for both treated patients and controls. Adverse events were collected up to the last available follow up from starting of tocilizumab and/or methylprednisolone in treatment group and from hospital admission in the control group. The common terminology criteria for adverse event (CTCAE) version 5.0 was used. Standard of care and treatment procedures The diagnosis of COVID-19 was made with a positive RT-PCR assay performed on nasal swab or broncoalveolar lavage fluid according to World Health Organization interim guidance

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

[16]. Patients received treatment with oral hydroxychloroquine 400mg bid, unless glucose-6phosphate dehydrogenase deficient. Until March 24th, darunavir/ritonavir 800/100 qd was also administered [17]. Thereafter, the protocol was amended and darunavir/ritonavir was withdrawn [18]. Short-term antibiotic coverage was prescribed at admission. Low-molecularweight heparin prophylaxis was administered unless contraindicated. These treatments were defined as SOC. Since March 11th, we started adding tocilizumab to SOC in case of severe COVID-19 pneumonia and systemic inflammation. Tocilizumab was administered intravenously at the dose of 8mg/kg (maximum 800mg), with the possibility of repeating the dose after 24 hours if no response was obtained. Due to a temporary shortage of intravenous formulation, the available subcutaneous formulation (162 mg) was administered. Following an internal review of risks and benefits of steroid treatment in patients with severe COVID-19, since March 16th methylprednisolone (1mg/kg for 5 days intravenously, then 0.5mg/kg for 5 days) was included in the protocol. Tocilizumab was added in case of systemic inflammation or rapid respiratory function deterioration. Statistical analysis No sample-size calculations were performed. The primary end point was time to failure, defined as intubation and mechanical ventilation or death, whichever occurred first, within 30 days from the hospital admission. The secondary endpoint was overall survival (OS). Time was calculated from time of hospitalization for the comparison between tocilizumab/methylprednisolone/SOC and SOC patients and from the date of starting anti-inflammation treatment for the comparison among treatment groups. The landmark analysis was applied in order to minimize the potential immortal time bias that can arise in non-randomized studies and is related to the fact that patients treated after a longer time from admission must have not experienced the event up to that time, and that

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

patients with a very early event (e.g. death) were more likely assigned to the untreated group. This is a conservative analysis which reduced the risk that the treatment choice was motivated by the patient's disease course. Therefore, day 3 from hospital admission was set as a landmark time point: those who died, were intubated or discharged from the hospital before day 3 were excluded, while patients were included in the tocilizumab/methylprednisolone treatment group if the treatment was started within 3 days from hospital admission (see Figure 1). To minimize baseline differences between treated and untreated patients a propensity scorebased analysis was performed. Propensity score (PS) was derived by a logistic regression model including the following baseline variables: age, gender, presence of comorbidities and week of treatment start, ratio of partial pressure of arterial oxygen to fractional concentration of oxygen inspired air (PaO₂/FiO₂), non-invasive ventilation (NIV), time from symptoms onset to hospital admission, IL-6, ferritin, C-reactive protein (CRP) and d-dimer serum levels. Positivity assumption of PS was checked after the calculation. For each patient, the overlap weight (OW) based on PS was calculated [19]. To assess the balance of covariate distribution between the two groups, Cohen's standardized mean differences were calculated between the two groups in the original samples and after weighting. An absolute value of difference < 0.10 was considered an acceptable balance. The OW-weighted Cox proportional hazard regression model was used to calculate the adjusted hazard-ratio (HR_{OW}) of tocilizumab/methylprednisolone/SOC vs SOC patients. Weighted cumulative probability of failure or death was calculated by mean of Kaplan-Meier (KM) survival curves. To define risk factors associated with outcomes and to compare the three treatment groups, adjusted HRs were estimated by a multivariable Cox proportional hazard regression model. The same baseline variables used in the calculation of PS were considered for the multivariable analysis. To avoid overfitting, only those characteristics who showed a p-value

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

 ≤ 0.15 at univariable analysis and after inclusion in the multivariable model were considered, with age and gender forced into the model. For a better interpretation and to avoid the influence of outliers on estimation, the IL-6, ferritin, CRP and d-dimer were log-transformed before the analysis due to the highly skewed distribution. All results were reported as HR with 95% confidence interval (95%CI). A subgroup analysis was performed to assess if the treatment effect of tocilizumab versus methylprednisolone on primary outcome was different between subgroups defined according to categorized baseline variables. An interaction test was used to assess a different treatment effect in subgroups. The sensitivity analysis pre-planned, and the comparison between was tocilizumab/methylprednisolone/SOC and SOC patients was reassessed excluding from the SOC group the patients that received tocilizumab or methylprednisolone after 3 days from hospitalization. The PS and OW were recalculated. P was considered significant if ≤ 0.05 . Stata (v.16; StataCorp.) was used for the computation. **Results Patients** Overall, 215 patients were evaluated: 135 (62.8%) received tocilizumab/methylprednisolone within 3 days from hospitalization, 20 (12.9%) were treated after 3 days from hospitalization and were included in the SOC group, and 60 (38.7%) patients received only SOC. After excluding the patients who were discharged or developed a failure event (intubation or death) before the day 3 set for landmark analysis, 196 patients were included (130 tocilizumab/methylprednisolone/SOC and 66 SOC patients) (Figure 1). Patients were mainly male (67.4%), with a median age of 67.9 years (range, 30-100), and most of them (78.1%) had comorbidities (Table 1). The median PaO₂/FiO₂ was 200 mmHg (interquartile range, IQR 133-289), and 164 (83.7%) had severe pneumonia (PaO₂/FiO₂

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

<300mmHg). The median time from the onset of symptoms to anti-inflammatory treatment in 130 patients was 8 days, IQR: 9-15; range 5-23. Failure rate In univariable and multivariable analyses, older age, male gender, higher baseline inflammatory markers, especially IL-6, and PaO₂/FiO₂ < 100 mmHg were identified as risk factors for failure (Table 2). Differences between the two groups were consistently reduced after OW. OW weighted characteristics of two groups of patients are shown in Table 3. After a median follow-up of 49 days (range 4-70, IQR 30-56), 17 patients were intubated (14/130 in tocilizumab/methylprednisolone/SOC and 3/66 in SOC group) and 36 died (14/130 in tocilizumab/methylprednisolone/SOC and 22/66 in SOC group). Overall, 28 (21.5%) failure events were detected among tocilizumab/methylprednisolone/SOC patients and 25 (37.9%) among SOC patients. At day 14, the weighted failure-free survival was 86.5% (95%CI, 79.1-91.7) among tocilizumab/methylprednisolone/SOC and 75.8% (95%CI, 63.7-84.1) among SOC patients, while at 30 days (primary endpoint) it was, respectively, 80.8% (95%CI, 72.8-86.7) and 64.1% (95%CI, 51.3-74.0) (Figure 2). The Cox regression analysis adjusted by OW weighted propensity score estimated a significant effect of therapy in reducing the risk of failure (HR_{OW} = 0.4895%CI, 0.23-0.99; p=0.049). Tocilizumab/methylprednisolone treatment strategies Within the cohort of 130 treated patients, 45 (34.6%) received methylprednisolone, 29 (22.3%) tocilizumab and 56 (43.1%) combined therapy. Patients in combined treatment group were younger and with fewer comorbidities but with comparable inflammatory markers, the frequency of low PaO₂/FiO₂ and NIV (Table 4).

- 257 After a median follow-up of 53 days (range 4-70, interquartile range 33-57), 28 failures were
- observed: in 14/45 (31.1%) patients receiving methylprednisolone, 6/29 (20.7%) tocilizumab
- 259 (1 subcutaneously and 5 intravenously) and 8/56 (14.3%) in combined treatment group.
- 260 At 14 days of follow-up from treatment start, the failure-free survival (Figure 3) was 80%
- 261 (95%CI, 65.1-89.1) in methylprednisolone group, 79.3% (95%CI, 59.6-90.1) in tocilizumab
- 262 group and 87.5% (95 CI, 75.6-93.8) in combined therapy group. No significant differences
- between the three treatment groups were identified in a multivariable analysis adjusted for the
- baseline risk factors (p for heterogeneity among treatment groups= 0.45) (Table 5).
- 265 Overall survival (OS)
- A total of 45 deaths, 36 without a previous intubation, were registered during the follow-up:
- 267 23 (34.8%) were in the SOC and 22 (16.9%) in tocilizumab/methylprednisolone/SOC group.
- 268 At day 14 of follow-up, the OS was 92.7% (95%CI, 86.4-96.1) in
- 269 tocilizumab/methylprednisolone/SOC group and 78.2% (95%CI, 67.0-85.6) in SOC (Figure
- 270 4). At 30 days OS was, respectively, 85.9% (95%CI, 80.7-92.6) and 71.9% (95%CI, 59.9-
- 80.8), with a significant better survival in tocilizumab/methylprednisolone/SOC patients in
- OW analysis ($HR_{OW} = 0.41, 95\%$ CI: 0.19-0.89, p=0.025).
- 273 When considering only patients receiving tocilizumab/methylprednisolone/SOC, death
- occurred in 13/45 (28.9%) patients receiving methylprednisolone, 4/29 (13.8%) tocilizumab
- and 5/56 (8.9%) in those receiving combined therapy. At 30 days the OS was, 79.5% (95%CI,
- 276 64.2-88.8), 85.8% (95%CI, 66.5-94.4) and 90.9% (95%CI, 79.6-96.1) in patients treated,
- 277 respectively, with methylprednisolone, tocilizumab and combined therapy (adjusted p for
- 278 heterogeneity among treatments: 0.55).
- 279 Subgroup analyses
- 280 It was not possible to identify subgroups, based on demographic or clinical characteristics,
- 281 with different benefits of tocilizumab versus methylprednisolone or tocilizumab versus
- 282 combination therapy.

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

Sensitivity analyses

As sensitivity analysis, the we run comparison between tocilizumab/methylprednisolone/SOC and SOC patients excluding the 20 patients that received tocilizumab/methylprednisolone treatment after 3 days from hospital admission (6 methylprednisolone, 8 tocilizumab and 6 both), and experienced 5 (25%) failures. The weighted failure-free survival in the SOC group was now 72.5% (95%CI, 58.8-81.5) at 14 days and 67.1% (95%CI, 52.8-77.9) after 30 days. The OW weighted difference between tocilizumab/methylprednisolone/SOC and SOC patients was amplified (HR_{OW}=0.39; 95%CI, 0.17-0.89; p=0.026). Side effects Among 155 patients who received tocilizumab/methylprednisolone/SOC at any time, 106 (68%) developed ALT increase (grade 1-2: 98/155, 63% and grade 3: 8/155, 5%): 32.4% of those who received methylprednisolone/SOC and 77% of those who received tocilizumab/SOC +/- methylprednisolone. Microbiologically documented infections were recorded in 12 (7.7%) patients: 10 bloodstream infections, 2 ventilator-associated pneumonias and 2 urinary tract infections. In tocilizumab/methylprednisolone/SOC group, grade 4 transient neutropenia and grade 2 maculopapular rash occurred in 1 patient each. Among 60 SOC patients, grade 1-2 ALT increase occurred in 5 (8%) and 1 patient developed urinary tract infection. There were no cases of significant decrease of hemoglobin or platelet levels. **Discussion** In this observational study in not intubated patients with mainly severe COVID-19 pneumonia, the early addition of tocilizumab and/or methylprednisolone to SOC resulted in adjusted failure-free survival of 86.5% and 80.8% at day 14 and 30, which was, respectively, 10.7% and 16.7% higher than in SOC patients.

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

Even though only the minority of patients develop the severe form of COVID-19 (14% in the Chinese cohort of 72.314 patients), the outcomes in this group are poor, with 24.9% rate of failure (intubation or death) reported in 173 patients with severe disease [2, 20]. The observation that COVID-19-associated respiratory failure can be caused by cytokine storm rather than viral progression is the rationale for administering anti-inflammatory treatments, including tocilizumab [9, 10, 21]. The initial studies on tocilizumab in COVID-19 reported a clinical benefit in retrospective cohorts of 21 and 15 patients with moderate to critical COVID-19 pneumonia, in whom steroids were also administered [12, 22]. However, none of studies reported and evaluated the impact of steroid co-administration, nor included a control group which did not receive tocilizumab. Subsequently these treatments were recommended by Chinese Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (version 6 and 7) [14]. However, considering the rapid widespread increase in severe cases of COVID-19 worldwide, the availability and the cost of anti-IL-6 treatment might limit its use. Therefore, at the peak of COVID-19 epidemics in our city, we implemented the early use of corticosteroids and the use of subcutaneous tocilizumab if intravenous formulation was not readily available. We acknowledge that the benefit of subcutaneous formulation might be lower and slower than in case of intravenous drug, but no standard intravenous dose for COVID-19 has been established, as one study used 400 mg and the other the rage of doses from 80 mg to 600 mg, irrespective of the patients' weight [12, 22]. The first study that reported the impact of steroid treatment in COVID-19, showed that it was administered to 30.8% of patients, mainly in case of more severe disease, and was associated with a significant reduction of the risk of death in patients with ARDS (HR=0.38) [13]. While other cohorts reported steroid use in approximately 44% of severely ill patients, they did not analyze their influence on outcome [20, 23]. Subsequently, an observational study reported a benefit of early administration of steroid therapy on composite outcome of ICU admission, mechanical ventilation or death at 14 days (34.9% vs. 54.3%) and overall survival (86.4% vs.

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

73.7%) [24]. In addition to these data, we were able to demonstrate that, after minimizing as much as possible the differences between the groups through OW adjustment, the outcome of patients was better in case of early treatment with tocilizumab and/or methylprednisolone. Indeed, in SOC group the rate of failure at day 14 of 24.2% was very similar to what reported in other cohorts with severe pneumonia (24.9%), while it was reduced to 13.5% in our tocilizumab/methylprednisolone/SOC group [20]. Our data show that this benefit was also present with month-long follow up (overall HR_{ow} of 0.48), which is important in establishing long term prognosis of these patients. Moreover, the benefit of early tocilizumab/methylprednisolone was also noted on overall survival, both at 14 and 30 days (respectively, 92.7% vs. 78.2% and 85.9% vs. 71.9%). Compared to the study with steroid use only, the 14-day survival was higher in our cohort, providing background for the hypothesis that combined tocilizumab/steroid treatment might be warranted [24]. Finally, preliminary results of the RECOVERY trial reported higher survival rate in patients with severe COVID-19 pneumonia treated with dexamethasone, although the detailed results are not available yet. Interestingly, our observational study, which showed the effectives of early anti-inflammatory treatment in a cohort of non-intubated patients with severe COVID-19 pneumonia, documented that these patients were treated at a median time of 8 days after the onset of symptoms, which is exactly the time of initial cytokine storm, and therefore might be optimal for the effect of anti-inflammatory treatment. Consistent with other studies, we identified older age, high IL-6 levels and poor respiratory function as independent predictors of failure, with possible impact also of CRP and d-dimer levels [25]. Possibly due to a limited sample size, we were unable to document which of three treatment groups provided most benefit, and if there were predictors of better response to tocilizumab/methylprednisolone compared to methylprednisolone alone in any subset of patients. However, the rate of failure-free survival was the highest in the combination treatment group. In addition, based on our sensitivity analyses, adding the anti-inflammatory

treatment later after hospital admission might still provide some clinical benefit. In fact, including in the SOC group patients who received anti-inflammatory treatment later during the infectious course possibly reduced the difference between the study arms, highlighting the benefit of an early anti-inflammatory treatment. The limitations of this study include the non-randomized design, yet the inclusion of consecutive patients using the same SOC but not treated with tocilizumab or methylprednisolone, and adjustment for the outcome-associated variables, allowed to notice the improvement in patient outcomes. Nonetheless, it is possible that some benefit observed was partially due to general improvements in patient clinical care that occur with time. Additionally, this being a single-center experience might limit the applicability to other settings, since our hospital managed to rapidly increase the capacity for hospitalization and ventilation support, potentially improving general patient care. However, the adjustment for the differences between patient groups through propensity score and conservative approach with the use of landmark analysis were directly at minimizing the risk associated with an absence of randomization. Finally, we believe that the rate of failure observed in this study of at 14 days in those with severe COVID-19 treated with SOC and 7.3% tocilizumab/methylprednisolone might help to better define the expected rate of response and calculate the number of patients needed to include in the studies assessing various treatment options. Conclusion

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

In conclusion, the negative impact of immune response in COVID-19 might be mitigated by early administration of anti-inflammatory therapy with tocilizumab, methylprednisolone or both. Randomized studies are warranted to establish the best treatment options, their timing and limitations.

Acknowledgments

We would like to thank all the patients and the hospital staff, with particular mention of Mrs

Enrica Lombardi, who helped us to get through these difficult weeks.

This study was supported by the efforts of all members of GECOVID group.

Funding

No funding or sponsorship was received for this study or publication of this article.

Independently of the study, Roche provided intravenous tocilizumab free of charge for the Ligurian Region during the first weeks of COVID-19 epidemics.

Some of the patients were included also in the observational Italian national AIFA study on intravenous tocilizumab.

References

- 398 [1] Zhou F, Yu T, Du R, et al. (2020) Clinical course and risk factors for mortality of
- 399 adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet
- 400 395(10229): 1054-1062. 10.1016/s0140-6736(20)30566-3
- 401 [2] Wu Z, McGoogan JM (2020) Characteristics of and Important Lessons From the
- 402 Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314
- 403 Cases From the Chinese Center for Disease Control and Prevention. JAMA.
- 404 10.1001/jama.2020.2648
- 405 [3] Grasselli G, Zangrillo A, Zanella A, et al. (2020) Baseline Characteristics and
- 406 Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy
- 407 Region, Italy. JAMA. 10.1001/jama.2020.5394
- 408 [4] Severe acute respiratory infections treatment centre: practical manual to set up and
- 409 manage a SARI treatment centre and SARI screening facility in health care facilities. Geneva:
- 410 World Health Organization; 2020 (WHO/2019-nCoV/SARI_treatment_center/2020.1.
- 411 [5] Yang X, Yu Y, Xu J, et al. (2020) Clinical course and outcomes of critically ill
- 412 patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective,
- 413 observational study. Lancet Respir Med. 10.1016/S2213-2600(20)30079-5
- 414 [6] Richardson S, Hirsch JS, Narasimhan M, et al. (2020) Presenting Characteristics,
- 415 Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the
- 416 New York City Area. JAMA. 10.1001/jama.2020.6775
- 417 [7] Clinical management of severe acute respiratory infection (SARI) when COVID-19
- disease is suspected. Interim guidance 13 March 2020. WHO/2019-nCoV/clinical/2020.4.
- 419 [8] Russell CD, Millar JE, Baillie JK (2020) Clinical evidence does not support
- 420 corticosteroid treatment for 2019-nCoV lung injury. The Lancet 395(10223): 473-475.
- 421 10.1016/S0140-6736(20)30317-2

- 422 [9] Zhang W, Zhao Y, Zhang F, et al. (2020) The use of anti-inflammatory drugs in the
- 423 treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of
- 424 clinical immunologists from China. Clin Immunol 214: 108393-108393.
- 425 10.1016/j.clim.2020.108393
- 426 [10] Siddiqi HK, Mehra MR COVID-19 Illness in Native and Immunosuppressed States: A
- 427 Clinical-Therapeutic Staging Proposal. The Journal of Heart and Lung Transplantation.
- 428 10.1016/j.healun.2020.03.012
- 429 [11] Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB (2020) Pharmacologic
- 430 Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA.
- 431 10.1001/jama.2020.6019
- 432 [12] Xu X, Han M, Li T, et al. (2020) Effective treatment of severe COVID-19 patients
- 433 with tocilizumab. ChinaXiv
- 434 [13] Wu C, Chen X, Cai Y, et al. (2020) Risk Factors Associated With Acute Respiratory
- 435 Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in
- 436 Wuhan, China. JAMA internal medicine. 10.1001/jamainternmed.2020.0994
- 437 [14] Chinese Clinical Guidance for COVID-19 Pneumonia Diagnosis and Treatment (7th
- edition). March 4, 2020. Issued by: China National Health Commission.
- 439 [15] (2018) From Liguria HIV Web to Liguria Infectious Diseases Network: How a Digital
- 440 Platform Improved Doctors' Work and Patients' Care. AIDS Research and Human
- 441 Retroviruses 34(3): 239-240. 10.1089/aid.2017.0064
- 442 [16] WHO (2020) Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected
- 443 human cases. 2020. https://www.who.int/publications-detail/laboratory-testing-for-2019-
- 444 novel-coronavirus-in-suspected-humancases-.
- 445 [17] Bassetti M, Giacobbe DR, Aliberti S, Barisione E, Centanni S, De Rosa FG, Di Marco
- 446 F, Gori A, Granata G, Mikulska M, et al: Balancing evidence and frontline experience in the
- early phases of the COVID-19 pandemic: current position of the Italian Society of Anti-

- Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). Clin Microbiol Infect
- 449 2020. Accepted for publication.
- 450 [18] Cao B, Wang Y, Wen D, et al. (2020) A Trial of Lopinavir-Ritonavir in Adults
- 451 Hospitalized with Severe Covid-19. N Engl J Med. 10.1056/NEJMoa2001282
- 452 [19] Thomas LE, Li F, Pencina MJ (2020) Overlap Weighting: A Propensity Score Method
- 453 That Mimics Attributes of a Randomized Clinical Trial. JAMA. 10.1001/jama.2020.7819
- 454 [20] Guan WJ, Ni ZY, Hu Y, et al. (2020) Clinical Characteristics of Coronavirus Disease
- 455 2019 in China. N Engl J Med. 10.1056/NEJMoa2002032
- 456 [21] Zhang C, Wu Z, Li J-W, Zhao H, Wang G-Q (2020) The cytokine release syndrome
- 457 (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may
- 458 be the key to reduce the mortality. International journal of antimicrobial agents: 105954-
- 459 105954. 10.1016/j.ijantimicag.2020.105954
- 460 [22] Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J (2020) Tocilizumab treatment in COVID-19:
- 461 A single center experience. J Med Virol. 10.1002/jmv.25801
- 462 [23] Wang D, Hu B, Hu C, et al. (2020) Clinical Characteristics of 138 Hospitalized
- 463 Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA.
- 464 10.1001/jama.2020.1585
- Fadel R, Morrison AR, Vahia A, et al. (2020) Early Short Course Corticosteroids in
- 466 Hospitalized Patients with COVID-19. Clin Infect Dis. 10.1093/cid/ciaa601
- 467 [25] Ruan Q, Yang K, Wang W, Jiang L, Song J (2020) Clinical predictors of mortality due
- 468 to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care
- 469 Med. 10.1007/s00134-020-05991-x

471

474 Tables

475 **Table 1**

476 Unweighted patients' characteristics stratified for treatment group.

Characteristics	All (n=196)	Tocilizumab/	SOC (n=66)	Standardized
		methylprednisolone/SOC		difference
		(n=130)		
Age, mean (SD); median	67.5 (13.7); 67.9 (32-	64.5 (12.4); 65 (32-91)	73.5 (14.4); 76.2 (39-	0.67
(range)	100)		100)	
Sex (male/female), n (%)	132/64 (67.4/32.7)	91/39 (70/30)	41/25 (62.1/37.9)	0.17
Any comorbidity, n (%)	153 (78.1)	198 (75.4)	55 (83.3)	0.19
Hypertension	77 (39.3)	48 (36.9)	29 (43.9)	
Diabetes	30 (15.3)	22 (16.9)	8 (12.1)	
Cancer	22 (11.2)	15 (11.5)	7 (10.6)	
Obesity	10 (5.1)	8 (6.2)	2 (3.0)	
Ischemic heart failure	22 (11.2)	11 (8.5)	11 (16.7)	
Hospital admission period				
≤ 11 th week of 2020	78 (39.8)	29 (22.3)	49 (74.2)	1.21
12 th week of 2020	66 (33.7)	51 (39.2)	15 (22.7)	0.36
13 th - 14 th week of 2020	52 (26.5)	50 (38.5)	2 (3.1)	0.97
Days from symptoms to	6.8 (4.1); 7 (0-24)	7.5 (4.1); 7 (0-24)	5.6 (4.0); 5 (0-19)	0.47
hospital admission, mean				
(SD); median (range)				
IL-6, mean (SD), median	60.3 (120.3), 36.9 (22-	69.7 (144.8), 40 (27-73)	41.9 (36.1), 31.5 (16-	0.26
(IQR), ng/L	64)		56)	
Ferritin, mean (SD), median	1076 (1060), 762	1251.4 (1194.4), 835	730.2 (596.7), 588	0.55
(IQR), μg/L	(452-1424)	(526-1656)	(316-900)	
CRP, mean (SD), median	100.8 (85.3), 81 (40-	112 (91.3), 90 (45-147)	78.8 (67.2), 65 (30-	0.41
(IQR), mg/L	132)		102)	
D-dimer, mean (SD), median	2340 (4091), 1125	2319 (4441), 1100 (670-	2382 (3327), 1173	0.02

(IQR), μg/L	(665-1730)	1569)	(651-2806)	
PaO ₂ /FiO ₂ , mean (SD),	221 (108), 200 (133-	214.8 (97.8) 199 (134-	232.9 (124.3), 208	0.30
median (IQR), mmHg	289)	277)	(130-308)	
PaO ₂ /FiO ₂ < 100 mmHg	22 (11.2)	13 (10)	9 (13.6)	0.11
PaO ₂ /FiO ₂ < 200 mmHg	93 (47.5)	65 (50)	28 (42.4)	0.15
NIV, n (%)	73 (37.2)	64 (49.2)	9 (13.6)	0.63
Anti-inflammatory treatment				
Steroids only	-	45 (34.6)	-	-
Tocilizumab only	-	29 (22.3)	-	
Combination treatment	-	56 (43.1)		
Number of doses				
tocilizumab				
0		45 (34.6)	-	-
1	-	74 (56.9)	-	-
2	-	11 (8.5)	-	-
Route of administration of				
tocilizumab				
Intravenous	-	49 (57.6)	-	-
Subcutaneous	-	36 (42.4)	-	-

⁴⁷⁷ CRP, C reactive protein; IL-6, interleukin 6; NIV, non invasive ventilation; PaO₂/FiO₂, ratio

of partial pressure of arterial oxygen to fractional concentration of oxygen inspired air; SOC,

standard of care.

Table 2

480

481 Univariable and multivariable analyses of risk factors for failure.

Factors	Univariable		Multivariable	
	HR (95% CI)	p-value	HR (95% CI)	p-value
Age (1-year change)	1.05 (1.03-1.07)	<0.001	1.05 (1.01-1.07)	<0.001
Sex (male vs. female)	1.91 (1.05-3.45)	0.033	1.77 (0.96-3.25)	0.066
Any comorbidity (Yes vs.	3.85 (1.55-9.60)	0.004		
No)* Treatment period		0.17		
•		0.17		
≤ 11 th week of 2020	1.00 (ref)			
12 th week of 2020	0.90 (0.52-1.56)			
13 th - 14 th week of 2020	0.54 (0.27-1.07)			
Time from symptoms (>7 vs	1.01 (0.61-1.67)	0.97		
≤ 7 days)				
IL-6 (1-unit on log-scale)	1.84 (1.45-2.33)	<0.001	1.70 (1.30-2.23)	< 0.001
Ferritin (1-unit on log-scale)	1.10 (0.84-1.44)	0.47		
CRP (1-unit on log-scale)	1.61 (1.21-2.16)	0.001		
D-dimer (1-unit on log scale)	1.50 (1.20 - 1.87)	<0.001		
PaO ₂ /FiO ₂ <100 vs ≥100	3.12 (1.79-5.45)	<0.001	1.95 (1.10-3.46)	0.023
NIV	1.28 (0.78-2.09)	0.33		

⁴⁸² CRP, C reactive protein; HR: hazard-ratio; IL-6, interleukin 6; NIV, non invasive ventilation;

484 inspired air.

PaO₂/FiO₂, ratio of partial pressure of arterial oxygen to fractional concentration of oxygen

- *None of the following single comorbidities resulted significant in multivariable analysis:
- 486 hypertension, diabetes, cancer, obesity, ischemic heart failure, and only ischemic hear disease
- 487 was significant in univariate analysis.

Table 3

489

490

OW weighted patients' characteristics stratified for treatment group

Characteristics	Tocilizumab/methilprednisolone/SOC	SOC (n=66)	Standardized
	(n=130)		weighted
			difference
Age, mean (SD);	68.4 (11.7); 68.3 (57.4-77.3)	68.4 (13); 68	0.000
median (IQR)		(59.2-76.9)	
Sex (male/female), n	87/43 (67/33)	44/22 (67/33)	0.000
(%)			
Any comorbidity, n (%)	102 (78.8)	52 (78.8)	0.000
Treatment period			
≤ 11 th week of 2020	68 (52.1)	35 (52.1)	0.000
12 th week of 2020	52 (40.0)	26 (40)	0.000
13 th - 14 th week of 2020	10 (7.9)	5 (7.9)	0.000
Days from symptoms to	7 (3.6); 7 (4-9)	6.8 (4.2); 7 (3-9)	0.071
hospital admission,			
mean (SD); median			
(IQR)			
Il-6, mean (SD); median	45.2 (55.7); 37 (26-51)	45.2 (36.8); 32.4	0.000
(IQR), ng/L		(17-64)	
Ferritin, median (IQR),	901 (671);	901 (727);	0.000
μg/L	762 (491-1095)	706 (479-995)	
PCR, median (IQR),	90.6 (65.3); 73 (43-124)	90.6 (83.3); 63.1	0.000
mg/L		(30-131)	

D-dimer, median (IQR)	1764 (3110); 1080 (680-1500)	1764 (2372);	0.000
		1030 (651-1691)	
PaO ₂ /FiO ₂ , mean (SD);	211.6 (96.1); 196 (144-280)	211.6 (118); 180	0.000
median (IQR), μg/L		(123-291)	
NIV, n (%)	53 (41.1)	27 (41.1)	0.000

NIV, non invasive ventilation; OW: overlap weights; PaO₂/FiO₂, ratio of partial pressure of arterial oxygen to fractional concentration of oxygen inspired air; SOC, standard of care.

Table 4
 Clinical and demographic characteristics in treated patients included in outcome analyses

Characteristics	Methylprednisolone	Tocilizumab	Combined
	(n=45)	(n=29)	(n=56)
Age, mean (SD); median (range)	67.5 (13.9); 68.2	65.9 (10.2);	61 (11.7); 63
	(37-91)	67.4 (42-80)	(32-85)
Sex (male/female), n (%)	32/13 (71.1/28.9)	24/5 (82.8/17.2)	35/21
			(62.5/37.5)
Any comorbidity, n (%)	36 (80)	23 (79.3)	39 (69.6)
Treatment period			
≤ 11 th week of 2020	4 (8.9)	22 (75.8)	3 (5.4)
12 th week of 2020	30 (66.7)	6 (20.7)	15 (26.8)
13 th - 14 th week of 2020	11 (24.4)	1 (3.5)	38 (67.9)
Days from symptoms to hospital	7.2 (4.7); 7 (0-21)	7.7 (3.5); 8 (1-	7.6 (3.8); 7 (2-
admission, mean (SD); median		15)	24)
(range)			
IL-6, median (IQR), ng/L	40 (22-68)	45 (33-88)	37 (27-63)
Ferritin, median (IQR), µg/L	741 (380-1087)	1422 (845-	760 (444-
		1846)	1858)
CRP, median (IQR), mg/L	82 (43-124)	121 (52-218)	88 (44-153)
D-dimer, median (IQR), μg/L	1080 (730-1600)	1280 (950-	1055 (618-
		2500)	1411)
PaO ₂ /FiO ₂ , median (IQR), mmHg	201 (156-311)	203 (144-280)	190 (125-254)
PaO ₂ /FiO ₂ < 100 mmHg	6 (13.3)	1 (3.5)	6 (10.7)
PaO ₂ /FiO ₂ < 200 mmHg	22 (48.9)	13 (44.8)	30 (53.6)

NIV, n (%)	20 (44.4)	13 (44.8)	31 (55.4)
Number of doses tocilizumab			
0		-	-
1		22 (75.9)	54 (96.4)
2		7 (24.1)	2 (3.6)
Route of administration of			
tocilizumab			
Intravenous		18 (62.1)	31 (55.4)
Subcutaneous		11 (37.9)	25 (44.6)

⁴⁹⁴ CRP, C reactive protein; IL-6, interleukin 6; NIV, non invasive ventilation; PaO₂/FiO₂, ratio

of partial pressure of arterial oxygen to fractional concentration of oxygen inspired air.

497 Table 5

499

500

Univariable and multivariable analyses for risk factors of failure endpoint in patients treated with tocilizumab and/or methylprednisolone and standard of care (SOC).

Factors	Univariable		Multivariable	
	HR (95% CI)	p-value	HR (95% CI)	p-value
Treatment		0.17		0.45
Methylprednisolone	1.00 (ref)		1.00 (ref)	
Tocilizumab	0.69 (0.27-1.81)		0.65 (0.23-1.82)	
Combined	0.45 (0.19-1.06)		0.59 (0.24-1.43)	
Age (1-year change)	1.05 (1.02-1.09)	0.002	1.05 (1.01-1.09)	0.012
Sex (male vs. female)	1.68 (0.68-4.14)	0.26	1.54 (0.61-3.91)	0.37
Any comorbidity (Yes vs.	4.76 (1.13-20.04)	0.034	-	
No)				
Treatment period		0.46		
≤ 11 th week of 2020	1.00 (ref)		-	
12 th week of 2020	1.03 (0.41-2.59)		-	
13 th - 14 th week of 2020	0.62 (0.22-1.70)		-	
Time from symptoms (>7	0.93 (0.44-1.98)	0.86	-	
$vs \le 7 \text{ days}$				
Il-6 (1-unit on log-scale)	1.93 (1.38-2.70)	<0.001	1.87 (1.29-2.71)	0.001
Ferritin (1-unit on log-	1.20 (0.78-1.83)	0.41	-	
scale)				


CRP (1-unit on log-scale)	1.62 (1.02-2.57)	0.04	-	
D-dimer (1-unit on log	1.62 (1.19 - 2.21)	0.002	-	
scale)				
PaO ₂ /FiO ₂ <100 vs ≥100	2.70 (1.09-6.66)	0.032	1.88 (0.72-4.70)	0.14
mmHg				
NIV	1.99 (0.90-4.40)	0.090	-	

502 CRP, C reactive protein; HR: hazard-ratio; IL-6, interleukin 6; NIV, non invasive ventilation;


PaO₂/FiO₂, ratio of partial pressure of arterial oxygen to fractional concentration of oxygen

inspired air.

505 Figure legends 506 Figure 1 507 The flowchart of the included patients. 508 509 Figure 2 510 Adjusted failure-free (intubation or death) survival in patients who received tocilizumab 511 and/or methylprednisolone and standard of care (SOC) vs. SOC. 512 513 Figure 3 514 Adjusted failure-free survival in patients receiving anti-inflammatory treatment: tocilizumab 515 only, methylprednisolone only, and combined treatment. 516 517 Figure 4 518 Adjusted overall survival in patients who received tocilizumab and/or methylprednisolone and 519 standard of care (SOC) vs. SOC. 520




^{*} These two groups were included in the main landmark analysis




Patients at risk

SOC 66 66 66 64 61 58 55 51 49 47 47 45 44 44 42 41 40 32 25 23 20 Tocilizumab/methyl+ 130 130 130 125 120 118 112 109 105 104 103 103 101 99 96 94 91 88 88 88 87 SOC



Steroids

Combined



SOC Tocilizumab/methyl + 130 130 130 128 127 126 121 119 115 114 112 112 111 109 106 104 SOC